Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation

Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1–20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon 14 mutations has demonstrated efficacy and tolerability in e...

Descripción completa

Detalles Bibliográficos
Autores principales: Brazel, Danielle, Zhang, Shannon, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113513/
https://www.ncbi.nlm.nih.gov/pubmed/35592355
http://dx.doi.org/10.2147/LCTT.S360574
_version_ 1784709597837131776
author Brazel, Danielle
Zhang, Shannon
Nagasaka, Misako
author_facet Brazel, Danielle
Zhang, Shannon
Nagasaka, Misako
author_sort Brazel, Danielle
collection PubMed
description Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1–20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon 14 mutations has demonstrated efficacy and tolerability in early trials. Here we focus on tepotinib and capmatinib in regards to molecular characteristics, early preclinical and clinical data, and the emerging role in future studies and clinical practice.
format Online
Article
Text
id pubmed-9113513
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-91135132022-05-18 Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation Brazel, Danielle Zhang, Shannon Nagasaka, Misako Lung Cancer (Auckl) Perspectives Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1–20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon 14 mutations has demonstrated efficacy and tolerability in early trials. Here we focus on tepotinib and capmatinib in regards to molecular characteristics, early preclinical and clinical data, and the emerging role in future studies and clinical practice. Dove 2022-05-13 /pmc/articles/PMC9113513/ /pubmed/35592355 http://dx.doi.org/10.2147/LCTT.S360574 Text en © 2022 Brazel et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Perspectives
Brazel, Danielle
Zhang, Shannon
Nagasaka, Misako
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
title Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
title_full Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
title_fullStr Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
title_full_unstemmed Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
title_short Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
title_sort spotlight on tepotinib and capmatinib for non-small cell lung cancer with met exon 14 skipping mutation
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113513/
https://www.ncbi.nlm.nih.gov/pubmed/35592355
http://dx.doi.org/10.2147/LCTT.S360574
work_keys_str_mv AT brazeldanielle spotlightontepotinibandcapmatinibfornonsmallcelllungcancerwithmetexon14skippingmutation
AT zhangshannon spotlightontepotinibandcapmatinibfornonsmallcelllungcancerwithmetexon14skippingmutation
AT nagasakamisako spotlightontepotinibandcapmatinibfornonsmallcelllungcancerwithmetexon14skippingmutation

Ejemplares similares